US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr
Summary
US20260098093A1, VISTA Molecules, Cancer Treatment, 9th Apr
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT AND PREVENTION OF CANCER USING VISTA ANTIGEN-BINDING MOLECULES
Application US20260098093A1 Kind: A1 Apr 09, 2026
Inventors
Bhushan Dharmadhikari, Olga Zharkova, Debleena Ray, Roberto Tirado-Magallanes, Dipti Thakkar, Konrad Paszkiewicz, Jerome Boyd-Kirkup, Piers Ingram
Abstract
VISTA antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, composition comprising, and methods using, the VISTA antigen-binding molecules.
CPC Classifications
C07K 16/2827 A61P 35/00 A61P 37/04 A61K 2039/505 C07K 2317/565 C07K 2317/567 C07K 2317/76 C07K 2317/92
Filing Date
2023-09-21
Application No.
19114367
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.